Are there physicochemical differences between allosteric and competitive ligands?
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Previous studies have compared the physicochemical properties of allosteric compounds to non-allosteric compounds. Those studies have found that allosteric compounds tend to be smaller, more rigid, more hydrophobic, and more drug-like than non-allosteric compounds. However, previous studies have not properly corrected for the fact that some protein targets have much more data than other systems. This generates concern regarding the possible skew that can be introduced by the inherent bias in the available data. Hence, this study aims to determine how robust the previous findings are to the addition of newer data. This study utilizes the Allosteric Database (ASD v3.0) and ChEMBL v20 to systematically obtain large datasets of both allosteric and competitive ligands. This dataset contains 70,219 and 9,511 unique ligands for the allosteric and competitive sets, respectively. Physically relevant compound descriptors were computed to examine the differences in their chemical properties. Particular attention was given to removing redundancy in the data and normalizing across ligand diversity and varied protein targets. The resulting distributions only show that allosteric ligands tend to be more aromatic and rigid and do not confirm the increase in hydrophobicity or difference in drug-likeness. These results are robust across different normalization schemes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig 2 ChemTreeMap [39] of the allosteric (blue) and competitive (red) ligands is a hierarchical tree based on grouping ligands by the Tc of the ECFP6 fingerprints. The size of each circle represents the number of ligands in a cluster of Tc ≥ 0.6. Though a few small regions of chemical space are dominated by one set or the other, the large number of branches with interdigitated red and blue circles shows that there is a great deal of chemical similarity between the allosteric and competitive ligands. To quantify the overlap, we should note that 623 out of 70,219 allosteric ligands (1%) are within Tc ≥ 0.6 of a competitive ligand, and 582 of the 9511 competitive ligands (6%) are within Tc ≥ 0.6 of an allosteric compound.](https://figures.cochat.ai/paper-figures/28a6a506ced145b4b1235f0b403b7658/are-there-physicochemical-differences-between-allosteric-and-competitive-ligands-figure-2.jpg)





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, non-covalent PPI inhibitors may have the ability to cause “off-target” effects due to binding to other molecules [114–116].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [116]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Individual Comparisons by Ranking Methods
Wilcoxon, F. (1945) · Biometrics Bulletin · doi:10.2307/3001968 · Cited by 15,354
On the nature of allosteric transitions: A plausible model
Monod, J., Wyman, J., & Changeux, J.-P. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80285-6 · Cited by 8,825
Extended-Connectivity Fingerprints
Rogers, D., & Hahn, M. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100050t · Cited by 7,524
ChEMBL: a large-scale bioactivity database for drug discovery
Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr777 · Cited by 4,382
Rapid and sensitive protein similarity searches
Lipman, D. J., & Pearson, W. R. (1985) · Science · doi:10.1126/science.2983426 · Cited by 4,033
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
DrugBank: a knowledgebase for drugs, drug actions and drug targets
Wishart, D. S., Knox, C., Guo, A. C., Cheng, D., Shrivastava, S., Tzur, D., Gautam, B., & Hassanali, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm958 · Cited by 2,861
DrugBank 3.0: a comprehensive resource for 'Omics' research on drugs
Knox, C., Law, V., Jewison, T., Liu, P., Ly, S., Frolkis, A., Pon, A., Banco, K., Mak, C., Neveu, V., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1126 · Cited by 1,831
Predicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667
Research works printed but not linked: 1
- Lu J, Carlson HA. ChemTreeMap: An Interactive Map of Biochemical Similarity in Molecular Datasets. Bioinformatics. 2016; 32(23): 3584– 92. doi: 10.1093/bioinformatics/btw523 27515740 PMC5181537 · DOI
Cited by
G protein-coupled receptors (GPCRs): advances in structures, mechanisms and drug discovery
Zhang, M., Chen, T., Lu, X., Lan, X., Chen, Z., & Lu, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01803-6 · Cited by 491
“20 25 Allosteric modulators are highlighted for their high subtype selectivity and low side effects.”
BackgroundAllosteric Modulator Discovery: From Serendipity to Structure-Based Design
Lu, S., He, X., Ni, D., & Zhang, J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01749 · Cited by 169
Lu, S., Shen, Q., & Zhang, J. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.8b00570 · Cited by 166
Ni, D., Lu, S., & Zhang, J. (2019) · Medicinal Research Reviews · doi:10.1002/med.21585 · Cited by 116
Integrated Computational Approaches and Tools for Allosteric Drug Discovery
Amamuddy, O. S., Veldman, W., Manyumwa, C. V., Khairallah, A., Agajanian, S., Odeyemi, O., Verkhivker, G. M., & Bishop, Ö. T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030847 · Cited by 118
“A study by Smith and colleagues hinted at the higher rigidity and aromaticity of allosteric modulators [121], thus providing an additional criterion for selecting modulators that are more likely to bind to an allosteric site.”
BackgroundThe design and development of covalent protein-protein interaction inhibitors for cancer treatment
Cheng, S.-S., Yang, G.-J., Wang, W., Leung, C.-H., & Ma, D.-L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00850-0 · Cited by 98
AlloFinder: a strategy for allosteric modulator discovery and allosterome analyses
Huang, M., Song, K., Liu, X., Lu, S., Shen, Q., Wang, R., Gao, J., Hong, Y., Li, Q., Ni, D., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky374 · Cited by 93
“Furthermore, it is well established that the physicochemical characteristics of allosteric modulators are divergent from orthosteric ligands (25,26).”
BackgroundAlong the allostery stream: Recent advances in computational methods for allosteric drug discovery
Ni, D., Chai, Z., Wang, Y., Li, M., Yu, Z., Liu, Y., Lu, S., & Zhang, J. (2022) · WIREs Computational Molecular Science · doi:10.1002/wcms.1585 · Cited by 68
“112,113 We also calculated and analyzed the general properties of allosteric and orthosteric sites and their residue compositions through quantitative comparative studies.”
BackgroundAllosteric modulation of GPCRs: From structural insights to in silico drug discovery
Persechino, M., Hedderich, J. B., Kolb, P., & Hilger, D. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108242 · Cited by 61
Steingruber, M., & Marschall, M. (2020) · Microorganisms · doi:10.3390/microorganisms8040515 · Cited by 45
“Such types of kinase inhibitory small molecules can either function through a shielding mechanism directed at one or several defined phosphorylation sites of a pUL97 substrate (phosphosite inhibitors) or it might cause a steric hindrance of pUL97 substrate recognition (allosteric assembly blockers of kinase-specific p…”
BackgroundMachine learning and protein allostery
Xiao, S., Verkhivker, G. M., & Tao, P. (2022) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2022.12.001 · Cited by 36
Probe Confined Dynamic Mapping for G Protein-Coupled Receptor Allosteric Site Prediction
Ciancetta, A., Gill, A. K., Ding, T., Karlov, D. S., Chalhoub, G., McCormick, P. J., & Tikhonova, I. G. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00802 · Cited by 29
“36,37 Thus, the probes derived from common/ privileged substructures of GPCR allosteric modulators could be more suitable for mapping GPCR allosteric sites.”
Characteristics of Allosteric Proteins, Sites, and Modulators
He, X., Ni, D., Lu, S., & Zhang, J. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8719-7_6 · Cited by 22
In Vitro and In Vivo Inhibition of MATE1 by Tyrosine Kinase Inhibitors
Uddin, M. E., Talebi, Z., Chen, S., Jin, Y., Gibson, A. A., Noonan, A. M., Cheng, X., Hu, S., & Sparreboom, A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122004 · Cited by 24
“This, in turn, provides a plausible explanation for the differential extent of total drug accumulation in the kidney, which is much less for oxaliplatin than for cisplatin [32,33].”
BackgroundMethodIdentification of allosteric inhibitor against AKT1 through structure-based virtual screening
Karunakaran, K., & Muniyan, R. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10582-7 · Cited by 21
“Studies have proven that the binding affinity of hydrophobic compounds are influenced by hydrophobic interaction than the hydrogen bonds [66] [67] In reference to the reported statements, hit 1, hit 2, hit 5, hit6 are hydrophobic in nature with high logp and aromatic rings (Fig.”
BackgroundExplaining and Predicting Allostery with Allosteric Database and Modern Analytical Techniques
Zha, J., Li, M., Kong, R., Lu, S., & Zhang, J. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167481 · Cited by 21
Frlan, R. (2022) · Antibiotics · doi:10.3390/antibiotics11050675 · Cited by 21
“Our results on the differences in druggability between the orthosteric and allosteric binding sites are consistent with data found in the literature [114,115].”
ResultAllosteric modulation of SHP2: Quest from known to unknown
Wang, N., Zhu, S., Lv, D., Wang, Y., Khawar, M. B., & Sun, H. (2023) · Drug Development Research · doi:10.1002/ddr.22100 · Cited by 12
“For instance, the orthosteric regulators is hydrophilically driven, while allosteric regulators and binding sites have predominantly hydrophobic interactions (Smith et al., 2017; van Westen et al., 2014).”
BackgroundAnnotation of Allosteric Compounds to Enhance Bioactivity Modeling for Class A GPCRs
Burggraaff, L., van Veen, A., Lam, C. C., van Vlijmen, H., IJzerman, A. P., & van Westen, G. J. P. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00695 · Cited by 12
Allostery Illuminated: Harnessing AI and Machine Learning for Drug Discovery
Blanco, M.-J., Buskes, M. J., Govindaraj, R. G., Ipsaro, J. J., Prescott-Roy, J., & Padyana, A. K. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00260 · Cited by 10
Irfan, A., Faisal, S., Ahmad, S., Saif, M. J., Zahoor, A. F., Khan, S. G., Javid, J., Al‐Hussain, S. A., Muhammed, M. T., & Zaki, M. E. A. (2023) · Biomedicines · doi:10.3390/biomedicines11113085 · Cited by 9
Analysis of the uncharted, druglike property space by self-organizing maps
Takács, G., Sándor, M., Szalai, Z., Kiss, R., & Balogh, G. T. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10343-y · Cited by 9
Specifics of Metabolite-Protein Interactions and Their Computational Analysis and Prediction
Walther, D. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2624-5_12 · Cited by 9
Progress in Allosteric Database
Song, K., Zhang, J., & Lu, S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8719-7_4 · Cited by 6
Alhosaini, K. A., Alanazi, M. M., Alsulaihim, I. N., Alonazi, A. S., Alasmari, F. F., & Khan, M. R. (2026) · Drug Development Research · doi:10.1002/ddr.70273 · Cited by 1
New modalities: Drugging the undruggable GPCR targets
Zawadzki, P., Graczyk, P. P., & Staroń, J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00030-3
Breaking Barriers: Latest Frontiers in GPCR Structural Analysis
Jawarkar, R. D., Ajmire, P. V., Wadekar, A., Dewani, A., & Mohale, D. (2026) · Springer eBooks · doi:10.1007/978-981-95-9081-0_5
BindingDB (2021) · UC San Diego · doi:10.7270/q2c53q9m
Metadata
- Authors
- Smith, R. D., Lu, J., & Carlson, H. A.
- Affiliations
- University of Michigan (US)
- Corresponding author
- Carlson, Heather A.
- Venue
- PLOS Computational Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-11-10
- Volume
- 13
- Issue
- 11
- Pages
- e1005813
- ISSN
- 1553-734X (ISSN-L)
- 1553-7358
- PMC
- PMC5699844
- OpenAlex
- W2767883384
- Cited by
- 27
- References
- 45
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 6 · 2021: 4 · 2020: 4 · 2019: 5 · 2018: 1
- FWCI
- 2.05
- Type
- journal article
- Language
- en
- Update notices
- new_version (2017-11-22)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Computational Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Ministry of Earth Sciences
- Ministry of Education, India
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Interaction Studies and Fluorescence Analysis
- Keywords
- allosteric ligands, physicochemical properties, drug-likeness, molecular descriptors, aromaticity, molecular rigidity, hydrophobicity, ChEMBL, data normalization, protein targets
- MeSH terms
- Algorithms, Allosteric Regulation, Allosteric Site, Chemistry, Physical, Ligands, Proteins, Databases, Factual, Computational Biology, Catalytic Domain, Hydrophobic and Hydrophilic Interactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.